Dramatic change in prescribing of hormone replacement therapy in The Netherlands after publication of the Million Women Study: a follow-up study. Br J Clin Pharmacol

Groningen University Institute for Drug Exploration, University of Groningen, Department of Social Pharmacy, Pharmacoepidemiology and Pharmacotherapy, Groningen, The Netherlands.
British Journal of Clinical Pharmacology (Impact Factor: 3.69). 01/2006; 60(6):641-7. DOI: 10.1111/j.1365-2125.2005.02502.x
Source: PubMed

ABSTRACT To estimate the diffusion of new safety information concerning postmenopausal hormonal replacement therapy (HRT) into prescribing practice in The Netherlands and to assess the impact of revised guidelines on the long-term treatment of HRT.
Cross-sectional study.
Community pharmacy dispensing data from a population of approximately 450,000 patients in the northern and eastern part of The Netherlands.
Women aged 45-69 years to whom at least one HRT prescription was dispensed between 1 January 2000 and 1 January 2004.
Annual and quarter prevalences of HRT and the proportion of new HRT users, switchers and continuous HRT users per quarter.
The prevalence of HRT prescribing decreased significantly from 107/1000 [95% confidence interval (CI) 104, 110] in 2000 to 87/1000 (95% CI 84, 89) in 2003. The decreasing prevalence was especially evident among the younger age groups and was most pronounced among users of oestrogen/progestagen combinations. The publication of the Women Health Initiative Study (WHI) was followed by a modest decrease in prescribing of HRT, whereas prescribing of HRT declined dramatically after publication of the Million Women Study (MWS) in August 2003. Among the continuous HRT users in the 4th quarter of 2002, 55% used HRT longer than 3 years. This percentage was 53 in the 4th quarter of 2003.
In contrast to the release of the WHI study results, publication of the MWS was followed by a dramatic fall in prescribing of HRT in The Netherlands. Despite the new recommendation that long-term HRT use should be discouraged, the proportion of long-term users did not change after the publication of the MWS.

  • Source
    • "The Minnesota Heart Survey found a dramatic decline in HRT among women with an intact uterus within the first 6 months following the preliminary WHI results whereas few women who underwent hysterectomy discontinued therapy [13]. Following WHI, the 2003 Million Women Study (MWS) results also had a large impact on the prescribing of HRT in The Netherlands, with a decrease from 107 per 1000 women in 2000 to 87 in 2003 [14]. In Ireland , the prevalence of HRT fell from 19.3% in 2002 to 16.0% in 2003 following WHI, and to 12.3% in 2004, after MWS [15]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: To survey the life prevalence and determinants of hormone replacement therapy (HRT) in Portugal. We evaluated 908 women with mean age (standard deviation) 62.3 (9.6) years, as part of the assembling of a cohort of adults, representative of Porto inhabitants. Extensive data collection was conducted and included socio-demographic, lifestyle and clinical characterisation. The latter comprised gynecologic and obstetric history, as well as lifetime use and duration of HRT. Life prevalence of hormone replacement therapy was 26.8% (95% confidence interval: 23.9-29.8). Prevalence of lifetime HRT was higher in younger (born after 1949: 37.1%) and more educated women (over 12 schooling years: 48.7%), as in white-collar workers (36.8%), and women using private healthcare (39.4%). HRT use was also more frequent among ever smokers (43.1%), and in women reporting regular sports practice (35.6%). Ever users of oral contraceptives underwent HRT more frequently (33.3%) and women who experienced menopause more recently were more likely to use HRT (after 1994: 40.5%). No differences were found in the prevalence of HRT according to whether women had been hysterectomised or oophorectomised. Education, regular sports practice and menopause year were independent determinants of HRT. Median duration of therapy was 2 years. Short-term HRT users were more educated, and had more recent menopause. Long-term HRT users were more educated, engaged in sports more frequently, and were more frequently oophorectomised. Prevalence of hormone replacement therapy increased until 2001 and was mainly determined by high socioeconomic status, regardless of important therapeutic indications, such as oophorectomy and hysterectomy.
    Maturitas 08/2007; 57(3):226-32. DOI:10.1016/j.maturitas.2006.12.005 · 2.86 Impact Factor
  • Source
    • "Using the SEER incidence data, we first calculated cumulative CRC incidence within the following 10 years among men and women for each single year of age between ages 50 and 75. The cumulative incidence within a given age range approximates the expected risk of developing a disease within the defined age interval in the absence of competing causes of death, assuming that age specific incidence rates remain constant over time (Day, 1987). Starting from the levels of 10-year cumulative incidence among men at ages 50, 55, and 60 (the most commonly implemented ages for initiation of CRC screening in existing programmes), we determined at what ages the same levels of 10-year cumulative incidence were observed among women. "
    [Show abstract] [Hide abstract]
    ABSTRACT: There is some variation regarding age at initiation of screening for colorectal cancer (CRC) between countries, but the same age of initiation is generally recommended for women and men within countries, despite important gender differences in the epidemiology of CRC. We have explored whether, and to what extent, these differences would be relevant regarding age at initiation of CRC screening. Using population-based cancer registry data from the US and national mortality statistics from different countries, we looked at cumulative 10-year incidence and mortality of CRC reached among men at ages 50, 55, and 60, and found that women mainly reached equivalent levels when 4 to 8 years older. The gender differences were remarkably constant across populations and over time. These patterns suggest that gender differentiation of age at initiation may be worthwhile to utilise CRC-screening resources more efficiently.
    British Journal of Cancer 04/2007; 96(5):828-31. DOI:10.1038/sj.bjc.6603628 · 4.82 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: There has been controversy about the results of the Women's Health Initiative and the Million Women Study and uncertainty about their impact on hormone therapy (HT) use. This study documents recent trends in HT use in postmenopausal women in the United Kingdom. Between April 2001 and September 2005, 202,638 postmenopausal women aged 50 to 74 and with no history of bilateral oophorectomy were recruited to the United Kingdom Collaborative Trial of Ovarian Cancer Screening. The proportion of women randomized each month who were using HT was calculated. The trend in HT use was assessed with reference to the publication of the Women's Health Initiative interim results (July 2002), the Million Women Study (August 2003), and advice from the UK Committee on Safety of Medicines (December 2003). The median number of women recruited and randomized per month was 3,955 (mean 3,744). The proportion of randomized women using HT between April 2001 and June 2002 was 29%. This was followed by a steady monthly decline, and by February to September 2005, only 10% to 11% of newly recruited women were using HT. This trend was present in all age groups. However, in current users, the average duration of HT use remained steady at 10 to 11 years. There was a steady decline in HT use among postmenopausal women at recruitment into the United Kingdom Collaborative Trial of Ovarian Cancer Screening between April 2001 and September 2005. This is likely to reflect general trends in the UK population and is probably related to the premature closure of the large HT trials and the ensuing publicity.
    Menopause 01/2007; 14(3 Pt 1):462-7. DOI:10.1097/01.gme.0000243569.70946.9d · 2.81 Impact Factor
Show more